XmAb18087 + XmAb18087 ± Pembrolizumab
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma, Small Cell Lung Cancer
Trial Timeline
May 10, 2021 → Mar 24, 2022
NCT ID
NCT04590781About XmAb18087 + XmAb18087 ± Pembrolizumab
XmAb18087 + XmAb18087 ± Pembrolizumab is a phase 1/2 stage product being developed by ICON plc. for Merkel Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04590781. Target conditions include Merkel Cell Carcinoma, Small Cell Lung Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04590781 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Merkel Cell Carcinoma